 TORONTO, Sept. 30, 2021 PRNewswire - Braxia Scientific Corp. Braxia, or the Company, CSE: BRAX OTC: BRAXF FWB: 496, a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to report encouraging preliminary findings of a recent clinical study that suggests ketamine may be as effective as a standalone antidepressant, versus as an adjunctive therapy. 